This site is intended for US audiences only.

This site is intended for US audiences only.

REVLIMID is a prescription medicine used to treat adults with follicular lymphoma (FL) or marginal zone lymphoma (MZL) in combination with a rituximab product, and who have previously been treated for their FL or MZL. FL and MZL are types of cancer of white blood cells called B-cell lymphocytes that are found in the lymph nodes and spleen. REVLIMID should not be used to treat people who have chronic lymphocytic leukemia (CLL) unless they are participants in a controlled clinical trial. It is not known if REVLIMID is safe and effective in children.

The REMS Companion App

Easily access the
Lenalidomide REMS program.

Download now

You have our support

Find resources and support for yourself or a loved one
Hypothetical R² (REVLIMID® [lenalidomide] + rituximab) patient with relapsed/refractory follicular or marginal zone lymphoma

RESOURCES

Get helpful information
about R2

LEARN MORE

CONVERSATION STARTER

Want tips on how to talk about
follicular or marginal zone
lymphoma with your doctor
and family?

DOWNLOAD NOW
Hypothetical R² (REVLIMID® [lenalidomide] + rituximab) patient with relapsed/refractory follicular or marginal zone lymphoma talking to their doctor

BROCHURE & TREATMENT TRACKER

Here’s an overview of your R2
treatment, including what to expect
and a way to keep track of your plan.

DOWNLOAD NOW

PATIENT & CAREGIVER ORGANIZATIONS

Find organizations that
support follicular lymphoma
and marginal zone lymphoma

LEARN MORE
Hypothetical R² (REVLIMID® [lenalidomide] + rituximab) patient with relapsed/refractory follicular or marginal zone lymphoma and a loved one

DOWNLOADS

More tools and resources that you may find helpful when learning about R2 can be downloaded here